Risperidone Augmentation Dosing for OCD
For adults with OCD who have inadequate response to SSRI monotherapy, start risperidone at 0.5 mg daily and titrate gradually to a target dose of 1-3 mg/day, with most patients responding at 2 mg/day or less.
Evidence-Based Dosing Strategy
The most robust evidence comes from multiple controlled trials demonstrating efficacy at relatively low doses:
- Starting dose: 0.5 mg daily 1, 2
- Target dose range: 1-3 mg/day 1, 2
- Typical effective dose: 2-2.3 mg/day (mean in clinical trials) 3
- Maximum studied dose: 3-4 mg/day 4, 2
Titration Schedule
Begin with 0.5 mg daily and increase gradually over 1-2 weeks based on tolerability. The evidence shows that even very low doses (0.5 mg) can be effective in SSRI-refractory OCD patients 1. Most patients who respond do so at doses ≤2 mg/day, and there is no clear evidence that higher doses provide additional benefit.
Clinical Trial Evidence
A pivotal double-blind RCT found that risperidone augmentation (0.5-3.0 mg/day) produced a 40% response rate versus 0% with placebo in treatment-resistant OCD 2. Another double-blind study demonstrated that 50% of patients responded to risperidone at just 0.5 mg/day when added to fluvoxamine 1.
However, the most important comparative study showed that cognitive-behavioral therapy (EX/RP) was significantly superior to risperidone augmentation (80% response rate for EX/RP vs. 23% for risperidone vs. 15% for placebo) 4. This suggests risperidone should be considered a second-line augmentation strategy when EX/RP is unavailable or not tolerated.
Important Clinical Considerations
Tolerability Profile
Risperidone is generally well-tolerated at these low doses, with the most common side effects being:
- Mild transient sedation
- Mild increase in appetite 1
- Rare mild extrapyramidal symptoms (tremor, akathisia) at doses ≥2 mg 5
Duration of Trial
Allow 8 weeks at therapeutic dose to assess response 2. Response is typically defined as ≥25-35% reduction in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) scores.
Predictors of Response
Better baseline insight into obsessions/compulsions significantly correlates with greater response to risperidone augmentation 2. Patients with comorbid bipolar disorder may show particularly robust responses 5, 6.
Comparative Effectiveness
Recent meta-analytic evidence ranks risperidone among the most effective antipsychotic augmentation agents for OCD, with a standardized mean difference of -0.74 compared to placebo 7. Risperidone demonstrates an optimal balance of efficacy and tolerability compared to other antipsychotics, making it a preferred first-choice augmenting agent when antipsychotic augmentation is indicated 7.
Critical Caveat
Despite these positive findings, EX/RP augmentation should be offered before antipsychotic augmentation given its superior efficacy (effect size approximately 4 times larger than risperidone) and more favorable side effect profile 4, 8.
Practical Algorithm
- Confirm adequate SSRI trial (≥12 weeks at therapeutic dose with good adherence)
- Offer EX/RP as first-line augmentation if available
- If EX/RP unavailable/declined/failed, consider risperidone:
- Start 0.5 mg daily
- Increase to 1-2 mg daily over 1-2 weeks
- Maximum 3 mg daily if no response at lower doses
- Continue for 8 weeks before declaring treatment failure
- Monitor for metabolic side effects and extrapyramidal symptoms
- If no response after 8 weeks at 2-3 mg/day, reassess diagnosis and consider alternative strategies
Do not routinely exceed 3 mg/day, as higher doses increase side effect risk without clear evidence of additional benefit in OCD specifically.